CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference
May 2, 2023CINCINNATI–(BUSINESS WIRE)–CinDome Pharma, a CinRx portfolio company, will present a poster at the 2023 Digestive Disease Week (DDW) Conference, held May 6th – 9th in Chicago, Illinois. The poster, titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study In Healthy Subjects” will highlight data on the promise of deudomperidone for the long-term management of gastroparesis.
Gastroparesis impacts an estimated 16 million people in the US and has suboptimal existing treatment options. Currently, the only US Food and Drug Administration approved treatment for gastroparesis is metoclopramide, which is only prescribed for short-term treatment and carries a black box warning. Domperidone, the first-line treatment in many countries outside the US, has not been approved in the US in part due to cardiovascular risk of QT prolongation and is prescribed for a limited dosing regimen. Deudomperidone, our modified formulation of domperidone designed to overcome historic challenges of domperidone, has the potential to be a new, safe, long-term treatment to address this unmet medical need.
Details of the poster presentation are as follows:
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Sponsor: AGA
Session Date and Time: May 7, 2023, from 12:30 PM to 1:30 PM
Poster Presentation Title: EFFECT OF THERAPEUTIC AND SUPRATHERAPEUTIC DOSES OF DEUDOMPERIDONE (CIN-102) ON CARDIAC REPOLARIZATION IN A THOROUGH QT (TQT) STUDY IN HEALTHY SUBJECTS
Poster Number: Su1638
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 6-9, 2023. The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
About CinRx Pharma
CinRx is a mosaic of biotechnology companies supported by a dedicated funding mechanism designed to improve drug development success and accelerate transformational new medicines to patients. By integrating our deep scientific, clinical, and operational expertise with a thoughtful portfolio model, we establish the optimal development trajectory – a drug development superhighway. The company’s experienced team ensures high-potential medicines are financially and operationally championed with the most efficient route from the lab to the patient. For more information, please visit www.CinRx.com or follow the company on Twitter and LinkedIn.
About CinDome Pharma
CinDome, a CinRx portfolio company, is dedicated to filling the significant need for a safe, effective and tolerable treatment for the millions of people living with the devastating impact of chronic gastroparesis. With nearly 16 million adult patients in the US experiencing symptoms of gastroparesis, a safe and effective treatment that can be taken on a chronic basis remains a significant unmet need. CinDome’s CIN-102 is an engineered formulation of domperidone, the first line treatment for gastroparesis worldwide, which is not approved in the US.
Contacts
CinRx Pharma Contact:
Jason Westerheide
Executive Director, Business Development
[email protected]
Media Contact:
Cassidy McClain
Account Director, Communications
[email protected]